These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35072890)

  • 1. Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan.
    Nakazawa T; Takahashi K; Kuwayama Y; Nomura A; Shimada F
    Adv Ther; 2022 Mar; 39(3):1359-1374. PubMed ID: 35072890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan.
    Miki A; Miyamoto E; Ishida N; Shii D; Hori K;
    Adv Ther; 2022 May; 39(5):2085-2095. PubMed ID: 35287233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
    Aihara M; Ropo A; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams N
    Jpn J Ophthalmol; 2020 Jul; 64(4):398-406. PubMed ID: 32572719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.
    Aihara M; Lu F; Kawata H; Iwata A; Odani-Kawabata N
    Jpn J Ophthalmol; 2021 Nov; 65(6):810-819. PubMed ID: 34495425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug.
    Sharif NA
    Curr Opin Pharmacol; 2024 Feb; 74():102426. PubMed ID: 38168596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omidenepag Isopropyl in Latanoprost Low/Nonresponders With Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 3, Nonrandomized, Two-Phase, Open-Label Study.
    Panarelli JF; Bowden EC; Tepedino ME; Odani-Kawabata N; Pei Z; McLaurin EB; Ropo A
    J Glaucoma; 2023 Dec; 32(12):999-1005. PubMed ID: 37853676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study.
    Tanihara H; Kakuda T; Sano T; Kanno T; Gunji R
    BMC Ophthalmol; 2020 Jul; 20(1):275. PubMed ID: 32646383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study.
    Aihara M; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams NK
    Am J Ophthalmol; 2020 Dec; 220():53-63. PubMed ID: 32533949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety.
    Kuwayama Y; Nomura A
    Adv Ther; 2014 Apr; 31(4):461-71. PubMed ID: 24615289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3).
    Bacharach J; Brubaker JW; Evans DG; Lu F; Odani-Kawabata N; Yamabe T; Wirta DL
    Am J Ophthalmol; 2024 Jul; 263():23-34. PubMed ID: 38395329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study.
    Tanihara H; Kakuda T; Sano T; Kanno T; Imada R; Shingaki W; Gunji R
    Adv Ther; 2019 Feb; 36(2):333-343. PubMed ID: 30610614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Efficacy of Omidenepag Isopropyl for Primary Open-Angle Glaucoma, Normal Tension Glaucoma, or Ocular Hypertension: A Meta-Analysis.
    Kuo HT; Yeh CY; Hsu AY; Ho JH; Lin CJ; Tsai YY
    J Ocul Pharmacol Ther; 2023 Dec; 39(10):705-715. PubMed ID: 37579061
    [No Abstract]   [Full Text] [Related]  

  • 13. Newly or switching effect of a selective EP2 agonist on intraocular pressure in Japanese patients with open-angle glaucoma.
    Ueda K; Sakata R; Fujishiro T; Honjo M; Shirato S; Aihara M
    Jpn J Ophthalmol; 2022 Sep; 66(5):434-439. PubMed ID: 35906503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial.
    Wang TH; Aung T; Lu DW; George R; Senthil S; Lu F; Odani-Kawabata N; Park KH
    Clin Ophthalmol; 2024; 18():2093-2106. PubMed ID: 39051019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
    Aihara M; Lu F; Kawata H; Iwata A; Liu K; Odani-Kawabata N; Shams NK
    J Glaucoma; 2019 May; 28(5):375-385. PubMed ID: 30839416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence.
    Kuwayama Y; Hashimoto M; Kakegawa R; Nomura A; Shimada F
    Adv Ther; 2017 Jun; 34(6):1411-1425. PubMed ID: 28502035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6).
    Olander KW; Sato MA; Abrams MA; Jerkins GW; Lu F; Dinh P; Odani-Kawabata N; Chabi A; Shams NK
    J Glaucoma; 2021 Jun; 30(6):473-480. PubMed ID: 33813559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months.
    Tanihara H; Kakuda T; Sano T; Kanno T; Kurihara Y
    Adv Ther; 2022 Apr; 39(4):1659-1677. PubMed ID: 35150417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.
    Fuwa M; Shimazaki A; Odani-Kawabata N; Kirihara T; Taniguchi T; Iwamura R; Yoneda K; Kato M; Morishima K; Shams NK
    J Ocul Pharmacol Ther; 2021 May; 37(4):223-229. PubMed ID: 33600237
    [No Abstract]   [Full Text] [Related]  

  • 20. Fixed Combination of Travoprost and Timolol Maleate Reduces Intraocular Pressure in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Prospective Multicenter Open-Label Study.
    Nakano T; Mizoue S; Fuse N; Iwase A; Matsumoto S; Yoshikawa K
    Adv Ther; 2015 Sep; 32(9):823-37. PubMed ID: 26424331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.